Table 2 Results of gene set enrichment analysis

AAV > HC

IL-6 pathway

26

89

100

< 0.001

0.0022

IL-5 pathway

25

63

69

< 0.001

0.014

Integrin-mediated cell adhesion

24

79

99

< 0.001

0.030

Insulin signalling pathway

38

128

159

< 0.001

0.049

MAPK signalling pathway

36

129

162

0.001

0.071

EGFR1 pathway

38

148

177

< 0.001

0.093

Focal adhesion

34

132

187

< 0.001

0.13

MAPK cascade

10

22

29

0.001

0.057

B cell receptor pathway

36

146

158

0.001

0.23

Regulation of actin cytoskeleton

25

95

146

0.005

0.33

IL-3 pathway

24

93

101

0.008

0.39

Pentose phosphate pathway

4

7

7

0.011

0.31

Glycogen metabolism

10

31

36

0.011

0.59

Proteasome degradation

16

59

61

0.014

0.62

Cytochrome P450

9

28

71

0.016

0.65

IL-1 pathway

11

35

38

0.017

0.57

Eicosanoid synthesis

6

16

19

0.030

0.67

AAV < HC

Ribosomal proteins

27

86

88

< 0.001

< 0.001

Homologous recombination

4

12

13

0.012

0.002

Inflammatory response pathway

5

21

33

0.029

0.071

Synthesis and degradation of ketone bodies

2

4

5

0.035

0.076

RV > HC

Proteasome degradation

9

59

61

< 0.001

0.020

Prostaglandin synthesis regulation

4

20

31

0.003

0.099

Apoptosis

6

76

82

0.019

0.80

Nucleotide GPCRs

2

10

105

0.037

0.54

Electron transport chain

6

87

105

0.042

0.93

RV < HC

Inflammatory response pathway

2

21

33

0.041

0.84

PAN > HC

Oxidative stress

3

18

28

0.010

0.31

Nucleotide GPCRs

2

10

11

0.016

0.44

Statin pathway

2

12

20

0.038

0.64

Eicosanoid synthesis

2

16

19

0.048

0.85

PAN < HC

Wnt signalling and pluripotency

4

64

97

0.015

0.83

TAK > HC

Apoptosis

4

76

82

0.008

0.63

Hypertrophy model

2

14

20

0.014

0.23

GPCRDB class A Rhodopsin-like

4

115

262

0.049

0.96

TAK < HC

S1P signalling

2

20

25

0.038

0.67